EMD Serono, Inc. and Fast Forward, LLC, a not-for-profit organization established by the National Multiple Sclerosis Society, announced the first four recipients of funding designed to speed research advances in mutually selected high potential areas of MS research.
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase 2 clinical trials.
Cytochroma announced positive Phase 1 results for CTAP201 Injection, a product being developed to treat secondary hyperparathyroidism in hemodialysis patients.
A single, very unusual family with Tourette syndrome (TS) has led Yale School of Medicine researchers to identify a rare mutation in a gene that is required to produce histamine.
New research on the properties of the clot-busting stroke drug tPA (tissue-type plasminogen activator) suggests that tPA can act as a neuroprotectant and may form the keystone of an adaptive response to a reduction in blood flow.
Merck and Ariad Pharmaceuticals are restructuring how they develop a potential cancer drug, with Merck saying it will cover all development costs in exchange for worldwide rights to the drug candidate.
Drugmaker Merck & Co. says a federal court jury has ruled in its favor in the second trial over whether its osteoporosis drug made teeth and jawbones deteriorate.
Aushon BioSystems, Inc. announced that the Institute for Molecular Medicine Finland (FIMM) will launch a cell microarray screening research program utilizing its 2470 Arrayer technology.
In a recently published paper, Lab901’s ScreenTape automated gel electrophoresis system demonstrated equivalence to - and improvements on - the accepted standard measurement of RNA sample quality control prior to microarray analysis.
Accelrys, Inc. announced the release of Accelrys Pipeline Pilot 8.0. This latest release of Accelrys’ scientific informatics platform has been further developed to support a greater number of scientists and researchers working individually or as collaborative teams.
VisEn Medical Inc. announced the commercial launch of its new VivoTag 645 red fluorescent dye for optimized labeling of biomolecules in a broad range of in vitro and in vivo research applications.
Harlan Laboratories, Inc., a leading contract research organization and research models and services company, has elected Hans Thunem the company’s new chief executive officer and board member.
CVS Caremark Corp. said its profit rose 4.5 percent in the first quarter, but said the mild cold and flu season hurt its sales.
Researchers at the Swedish medical university Karolinska Institutet have discovered a new control mechanism in our immune system.
A study at Columbia University's Mailman School of Public Health suggests that traumatic experiences "biologically embed" themselves in select genes, altering their functions and leading to the development of post-traumatic stress disorder.